Today, the European Commission has notified Lundbeck that it has opened
proceedings against Lundbeck. The purpose is to identify whether Lundbeck has
misused a dominant position or has been involved in anticompetitive agreements
in the markets for citalopram.
Lundbeck is cooperating fully with the European Commission. Lundbeck is
confident that the Group has complied with all relevant national and EU
competition legislation.
Financial guidance
The content of this release will have no influence on the Lundbeck Group's
financial result for 2009.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Mads Kronborg
Director, IR & Communication Media Relations
+45 36 43 30 79 +45 36 43 28 51
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26
Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improve the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose Lundbeck is
engaged in the research and development, production, marketing and sale of
pharmaceuticals across the world, targeted at disorders like depression and
anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and
employs today over 5,500 people worldwide. Lundbeck is one of the world's
leading pharmaceutical companies working with CNS disorders. In 2008, the
company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD
2.2 billion). For more information, please visit www.lundbeck.com.
[HUG#1371118]
